BCL2 and Hyperglycemia: HMGB1 inhibition effectively ameliorated hyperglycaemia-activated caspase-3 (P < 0.05; Fig. 6D) and decreased Bax/Bcl-2 ratio (P < 0.05; Fig. 6E and F).